Junhemeng Biopharmaceutical (Hangzhou)
Latest round
- Series C
Last raised
- Jun 2026
Total raised
- $108M
Investors
- 14
About Junhemeng Biopharmaceutical (Hangzhou)
, trading as Junhemeng Biopharmaceutical (Hangzhou), is a biopharmaceutical company that focuses on the R&D of recombinant protein drugs. It established approximately 8,000 square meters of GMP-level production bases in Hangzhou. Junhemeng Biopharmaceutical (Hangzhou) developed recombinant protein R&D platforms, covering recombinant protein express systems, separation and purification technologies, protein in vitro folding and self-assembly systems, and drug Long-lasting slow-release control technologies. Products include recombinant human collagen, recombinant botulinum toxin type A, recombinant growth hormone, etc. The company generates revenue by providing recombinant protein drugs.
Who invested in Junhemeng Biopharmaceutical (Hangzhou)
14 investors across 4 rounds
See all investors in Junhemeng Biopharmaceutical (Hangzhou)
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Junhemeng Biopharmaceutical (Hangzhou)
Who invested in Junhemeng Biopharmaceutical (Hangzhou)?
Junhemeng Biopharmaceutical (Hangzhou) has 14 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Junhemeng Biopharmaceutical (Hangzhou) raised?
Junhemeng Biopharmaceutical (Hangzhou) has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Junhemeng Biopharmaceutical (Hangzhou) last raise money?
Junhemeng Biopharmaceutical (Hangzhou)'s most recent round on record is a Series C, in Jun 2026.
What does Junhemeng Biopharmaceutical (Hangzhou) do?
, trading as Junhemeng Biopharmaceutical (Hangzhou), is a biopharmaceutical company that focuses on the R&D of recombinant protein drugs.
Where is Junhemeng Biopharmaceutical (Hangzhou) headquartered?
Junhemeng Biopharmaceutical (Hangzhou) is headquartered in Hangzhou, China.
Which VCs invest in companies like Junhemeng Biopharmaceutical (Hangzhou)?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Junhemeng Biopharmaceutical (Hangzhou)'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Junhemeng Biopharmaceutical (Hangzhou)? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.